Compare · PXMD vs VGR
PXMD vs VGR
Side-by-side comparison of PaxMedica Inc. (PXMD) and Vector Group Ltd. (VGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PXMD and VGR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- VGR carries a market cap of $1.74B.
- VGR has more recent analyst coverage (4 ratings vs 0 for PXMD).
- Company
- PaxMedica Inc.
- Vector Group Ltd.
- Price
- $0.72-3.73%
- $14.99+0.20%
- Market cap
- -
- $1.74B
- 1M return
- +0.00%
- -
- 1Y return
- +0.00%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 4
Vector Group Ltd.
Vector Group Ltd., through its subsidiaries, manufactures and sells cigarettes in the United States. It operates in two segments, Tobacco and Real Estate. The company produces cigarettes in 100 combinations under the EAGLE 20's, Pyramid, Montego, Grand Prix, Liggett Select, Eve, and USA brand names, as well as various partner and private label brands. In addition, it provides residential real estate brokerage, relocation, real estate sales and marketing, and title insurance services to real estate buyers and financial institutions; manages cooperative apartment buildings, condominium apartment buildings, and rental apartment buildings; and invests in, acquires, and owns real estate properties or projects, as well as develops land. Further, the company operates elliman.com, a website that enables consumers to search properties and access current market information, as well as offers building and neighborhood guides, and other interactive content. It markets and sells its cigarettes to wholesalers and distributors of tobacco and convenience products, as well as grocery, drug, and convenience store chains. The company was formerly known as Brooke Group Ltd. and changed its name to Vector Group Ltd. in May 2000. Vector Group Ltd. was founded in 1873 and is based in Miami, Florida.
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
Latest VGR
- SEC Form 15-12G filed by Vector Group Ltd.
- Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.